NCT06955468Completed
Evaluating a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
Development of a Bidirectional Priming Intervention for Goals-of-care Communication in Oncology
Source: ClinicalTrials.gov · Last updated 4 Mar 2026
Brief summary (registry, in English)
This pilot study will evaluate whether an intervention aimed at hospitalized patients with advanced lung and gastrointestinal cancers can help facilitate goals-of-care (GOC) communication with their oncologists after discharge. While GOC communication is a recommended component of routine oncology care, many patients with solid cancers do not have the opportunity to talk with their oncologist about their goals and end-of-life preferences. Prior research has shown that a systematic method of prompting GOC communication with at-risk patients would address a key barrier to timely GOC communication and ensure that patients receive care that is in line with their personal preferences. This trial will enroll 80 participants, who will be randomized 1:1 to either an intervention or a control group. Participants in the intervention group will complete a short survey regarding their goals, preferences, and disease understanding. Survey responses will be shared with each participant's outpatient oncology team. Oncologists will subsequently receive a nudge in the electronic medical record reminding them of key survey responses and encouraging them to discuss them at the patient's first clinic visit after hospital discharge. The primary feasibility outcome is intervention completion rate and the primary clinical outcome is GOC documentation within 30 days of discharge in the intervention group compared to the control group.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 40 (actual)
- First submitted
- 25 Apr 2025
- Start date
- 21 Jul 2025
- Primary completion date
- 26 Jan 2026
- Lead sponsor
- Abramson Cancer Center at Penn Medicine
- Diseases
- Lung cancer
- NCT number
- NCT06955468
What you commit to
- Study type: Interventional
- Participants enrolled: 40
- From 21 Jul 2025 to the primary completion date, 26 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- 1\. Unable to complete survey in English.
Who the study is looking for
- Unplanned admission to the HUP Solid Oncology service;
- Underlying diagnosis of advanced lung or GI cancer, defined as metastatic or locally advanced disease;
- Anticipated discharge within the next 72h; and
- Primary oncologist is based at HUP; or
- Family member/caregiver of a patient meeting the above 4 criteria.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Hospital of the University of Pennsylvania Coordinator of this site? Confirm its status | Philadelphia | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.